Cholesterol Playing Field Expands To Early Atherosclerosis, HDL, Novel Drugs

Pfizer is hoping to use the results of its failed torcetrapib trials as additional evidence of Lipitor's efficacy in halting progression of atherosclerosis, while competitor AstraZeneca offers new data to expand Crestor's use into early atherosclerosis